CCA
ALNA

Catalyst Capital Advisors’s Allena Pharmaceuticals ALNA Stock Holding History

Catalyst Capital Advisors’s Portfolio ALNA Stock Details ALNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-420
Closed -$4K – 582
2017
Q4 		$4K Buy
+420
New +$5.18K ﹤0.01% 408

Other funds holding ALNA

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PIM
Partner Investment Management San Francisco, California $13.9M AUM 55.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Catalyst Capital Advisors's ALNA Position: Q1 2018 in Review

Catalyst Capital Advisors sold out of Allena Pharmaceuticals (ALNA) in Q1 2018, closing a stake of 420 shares — an estimated $4K sold.

Catalyst Capital Advisors first reported a position in ALNA in Q4 2017 and held it in 1 quarter. The position peaked at $4K in Q4 2017. 42 funds tracked by Wall St. Rank hold ALNA as of Q1 2018.

  • Catalyst Capital Advisors reported no remaining Allena Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Catalyst Capital Advisors sold 420 Allena Pharmaceuticals shares in Q1 2018, an estimated $4K.
  • Catalyst Capital Advisors first reported a position in Allena Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Catalyst Capital Advisors's Allena Pharmaceuticals position peaked at $4K in Q4 2017.
  • 42 funds tracked by Wall St. Rank held Allena Pharmaceuticals as of Q1 2018.

Based on Catalyst Capital Advisors's 13F filing for Q1 2018, filed 18 May 2018.